Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged  ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

ConclusionThese results support the efficacious and safe continuous, long-term use of crisaborole for the management of mild-to-moderate AD.Trial RegistrationClinicalTrials.gov: NCT02118766, NCT02118792.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
More News: Dermatitis | Dermatology | Skin | Study